At a glance
- Originator Kaken Pharmaceutical
- Class Antihypertensives; Benzopyrans
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 26 May 2001 Profile reviewed but no significant changes made
- 20 May 1997 No-Development-Reported for Hypertension in Japan (Unknown route)